Parkinson Disease
One of the Largest-Ever Parkinson's Disease Studies Initiated Across the United States
Published in Biotech Business Week, April 16th, 2007
The study, which involves more than 50 sites and will enroll over 1,700 patients in the U.S. and Canada, is intended to test a new drug therapy, developed by Palo Alto-based Avicena Group, to slow the progress of Parkinson's disease and help millions of people around the world afflicted with this debilitating disease.
"This study will harness the expertise of some of the top researchers in the country," says Dr. Karl Kieburtz, lead investigator for the study. "Projects like this are evidence...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
More Articles from Biotech Business Week
- Addiction Medicine
Genes found for successful smoking cessation - Aging
It's never too late to get it back! Aging interrupted - Allergies
Nitric oxide allergic reaction linked to hayfever - Antibiotics
New Strain May Make a Common Bacterial Illness More Severe - Biophysics
Small Molecules Probe Proteins Deep Inside Cell Membrane - Bipolar Disorders
Intensive psychotherapy more effective than brief therapy for treating bipolar depression - More from this issue of Biotech Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
